- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/569 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone substituted in position 17 alpha, e.g. ethisterone
Patent holdings for IPC class A61K 31/569
Total number of patents in this class: 204
10-year publication summary
|
22
|
15
|
25
|
15
|
19
|
17
|
18
|
11
|
7
|
7
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Ellodi Pharmaceuticals, L.P., General Partner, Ellodi Development I Genpar, LLC, a Delaware limited liability company | 34 |
10 |
| Nicox Ophthalmics, Inc. | 21 |
8 |
| Allergan, Inc. | 2155 |
7 |
| The Johns Hopkins University | 5922 |
7 |
| Norton (Waterford) Limited | 223 |
7 |
| The University of Chicago | 1502 |
7 |
| Havah Therapeutics Pty Ltd | 19 |
7 |
| Regenera Pharma Ltd. | 24 |
6 |
| Shanghai AO Qi Medical Technology Co., Ltd. | 8 |
5 |
| Emory University | 1722 |
4 |
| Chemo Research, S.L. | 103 |
3 |
| Clinipro Co., Ltd. | 4 |
3 |
| Corcept Therapeutics, Inc. | 373 |
3 |
| Lipocine Inc. | 124 |
3 |
| Mati Therapeutics Inc. | 61 |
3 |
| Regeneron Pharmaceuticals, Inc. | 4790 |
3 |
| Changzhou Ruiming Pharmaceutical Company, LTD | 4 |
3 |
| Zhejiang Jiachi Development Pharmaceuticals Ltd | 9 |
3 |
| Legacy Pharma Inc. | 9 |
3 |
| Pfizer Inc. | 3413 |
2 |
| Other owners | 107 |